Oruka Therapeutics (ORKA) Income from Continuing Operations (2009 - 2026)
Oruka Therapeutics' Income from Continuing Operations was -$2.68 million in Q2 2024, compared with -$1.48 million a year earlier.
Powered by 
Analysis
Oruka Therapeutics (ORKA) Income from Continuing Operations (2009 - 2026) Analysis & Trends
On a trailing twelve-month basis, Oruka Therapeutics' Income from Continuing Operations was -$7.2 million through Jun 30, 2024; for FY2023, it came in at -$5.34 million.
- In earlier years, Income from Continuing Operations was -$9.92 million in FY2022, -$19.32 million in FY2021, -$9.74 million in FY2020 and -$5.48 million in FY2019.
- The Q2 2024 figure marks the lowest quarterly Income from Continuing Operations since Q2 2022.
- Per Business Quant data, ORKA's Income from Continuing Operations in the three quarters before Q2 2024 was -$2.01 million (Q1 2024), -$1.09 million (Q4 2023) and -$1.42 million (Q3 2023).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 6.45 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 4.22 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 5.07 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 4.80 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 3.86 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 2.43 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.25 Bn |
| 10 | Oruka Therapeutics | 7.43 Bn | 4.55 Bn | - | -49.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -49.97 Mn |
| Jun 30, 2026 | -41.21 Mn |
| Mar 31, 2026 | -31.83 Mn |
| Dec 31, 2025 | -29.58 Mn |
| Sep 30, 2025 | -30.27 Mn |
| Jun 30, 2025 | -24.57 Mn |
| Mar 31, 2025 | -20.99 Mn |
| Dec 31, 2024 | -26.70 Mn |
| Sep 30, 2024 | -27.62 Mn |
| Jun 30, 2024 | -1.93 Mn |
| Mar 31, 2024 | -1.80 Mn |
| Dec 31, 2023 | -1.09 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | -1.48 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | -1.17 Mn |
| Sep 30, 2022 | -2.33 Mn |
| Jun 30, 2022 | -3.15 Mn |
| Mar 31, 2022 | -3.27 Mn |
| Dec 31, 2021 | -5.68 Mn |
API Access
Oruka Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=ORKA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "ORKA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=ORKA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();